Marine Natural Products: A Source of Novel Anticancer Drugs
Open accessThe DOI matches its Crossref record; 215 of the 235 references it cites were found in a registry or an index; 37 of the 152 sources its claims cite were checked for support.
Abstract
Cancer remains one of the most lethal diseases worldwide. There is an urgent need for new drugs with novel modes of action and thus considerable research has been conducted for new anticancer drugs from natural sources, especially plants, microbes and marine organisms. Marine populations represent reservoirs of novel bioactive metabolites with diverse groups of chemical structures. This review highlights the impact of marine organisms, with particular emphasis on marine plants, algae, bacteria, actinomycetes, fungi, sponges and soft corals. Anti-cancer effects of marine natural products in in vitro and in vivo studies were first introduced; their activity in the prevention of tumor formation and the related compound-induced apoptosis and cytotoxicities were tackled. The possible molecular mechanisms behind the biological effects are also presented. The review highlights the diversity of marine organisms, novel chemical structures, and chemical property space. Finally, therapeutic strategies and the present use of marine-derived components, its future direction and limitations are discussed.
Overview
CoChat Summary
TL;DR
This review summarizes marine natural products as sources of novel anticancer drugs, covering marine plants, algae, bacteria, actinomycetes, fungi, sponges, and soft corals. It highlights cytotoxic and mechanistic findings, clinical candidates, and chemical property-space diversity, while noting that many marine compounds remain preclinical and the deep sea is largely unexplored.
Key findings
- Marine-derived compounds show anticancer activity across many tumor cell lines: cryptophycin 1 had IC50 = 0.005 and 0.003 ng/mL against KB and LOVO cells; coibamide A had LC50 < 23 nM against NCIH460 lung and mouse neuro-2a cells; salinosporamide A had IC50 = 0.13, 0.28, 7.5, and 35.0 µM against A-549, HL-60, BEL-7402, and P388 cells, respectively.
- The review reports 13 natural products isolated from marine organisms being tested in different phases of clinical trials; examples include bryostatin 1 in phase II, ET-743 in phase I, and dolastatin 10 in phase II. Marine-based drugs cited as used against leukemia, metastatic breast cancer, soft tissue sarcoma, and ovarian cancer include cytarabine, eribulin mesylate, brentuximab vedotin, and trabectidine.
- Marine biodiversity is described as vast: oceans cover over 70% of the earth, nearly 250,000 marine species are described, 99% of all bacteria cannot be cultured, and there are more than 22,000 known microbial secondary metabolites, 70% produced by actinomycetes, 20% by fungi, 7% by Bacillus spp., and 1–2% by other bacteria.
- ChemGPS-NP analysis using eight principal components based on 35 molecular descriptors showed that the reviewed marine compounds did not form tight clusters, indicating chemical diversity within classes such as marine peptides.
Methods
- Narrative review of marine natural products with anticancer activity, emphasizing marine plants, algae, bacteria, actinomycetes, fungi, sponges, and soft corals, and covering in vitro, in vivo, and clinical trial reports.
- For chemical property space, chemical structures were converted to SMILES using Chemsketch and submitted to ChemGPS-NPweb; eight principal component values were obtained from 35 molecular descriptors per compound, and PC1, PC2, and PC3 were plotted in three dimensions.
- Main analysis is qualitative synthesis of reported cytotoxic activities, mechanisms, and clinical status; no systematic search strategy, inclusion criteria, or quantitative meta-analysis is described.
Limitations
- Stated in the paper: sampling difficulties and the need for sufficiently large quantities for detailed analyses; less than 5% of the deep sea has been explored and less than 0.01% of the deep-sea floor sampled in detail; preclinical and clinical data for marine natural compound chemoprevention remain scant; NMR is less sensitive than MS and some compound classes cannot be detected by MS; many compounds such as calothrixins A/B, ulithiacyclamide, patellamide, borophycin, and largazole have not yet entered clinical trials; the exact mechanism of sansalvamide A is unknown.
- Evident from the text: as a narrative review, it lacks a systematic search strategy, formal inclusion/exclusion criteria, risk-of-bias assessment, and quantitative pooling, so the findings are illustrative rather than exhaustive.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
32 Valid · 3 Not valid · 64 Not checked · 11 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Advanced technology and extensive research on marine natural products have led to the discovery of a new generation of anticancer drugs currently used in clinical trials [6].”
§ Marine Natural Products: A Source of Novel Anticancer Drugs > 1. Introduction
What the sources say
- Partly supportedcites [6] Ang, 2000, In vivo antimalarial activity of the beta-carboline alkaloid manzamine A, Antimicrob. Agents Chemother. sourceExperimental — accuracy not yet measured
The Abstract (page not specified) says marine-sponge manzamines had attracted interest as potential anticancer agents and inhibited cancer-cell growth. It does not say that advanced technology produced a new generation of anticancer drugs or that any were in clinical trials; this paper reports antimalarial testing in mice. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Natural bioactive molecules exhibit cytotoxic effects by attacking macromolecules expressed by cancer cells, such as those in oncogenic signal transduction pathways [16].”
§ Marine Natural Products: A Source of Novel Anticancer Drugs > 1. Introduction
What the sources say
- Supportedcites [16] Nobili, 2009, Natural compounds for cancer treatment and prevention, Pharmacol. Res. source
The Conclusions describe natural compounds with cytotoxic activity that target macromolecules in cancer cells, including compounds targeting oncogenic signal-transduction pathways. The citing sentence paraphrases that distinction. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Over the past 50 years, emerging evidence has shown that many natural products derived from plants and microbes of marine origin (Table 1), exhibit beneficial effects in the prevention and treatment of cancer, i.e., cytarabine, eribulin mesylate, brentuximab vedotin, and trabectidine are marine-based drugs used against leukemia, metastatic breast cancer, soft tissue sarcoma and ovarian cancer [20,”
§ Marine Natural Products: A Source of Novel Anticancer Drugs > 2. Nature and Cancer Chemotherapy
What the sources say
- Partly supportedcites [20] Dyshlovoy, S.A., and Honecker, F. (2018). Marine compounds and cancer: 2017 updates. Mar. Drugs, 16. sourceExperimental — accuracy not yet measured
The paper’s main text reports anticancer activity in compounds from marine algae and microbes and identifies four marine-derived drugs approved to treat cancer. It does not establish beneficial effects in cancer prevention, so the prevention portion of the claim is unsupported. (LLM, conf=0.85)
- Not matchedcites [21] (2019, August 17). Drug Bank. Available online: http://www.drugbank.ca.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The bryostatin 1 has recently entered phase II clinical trial against melanoma, non-Hodgkin’s lymphoma, renal cancer and colorectal cancer [58,59,60].”
§ Marine Natural Products: A Source of Novel Anticancer Drugs > 5. From Marine Organisms to Anticancer Drugs
What the sources say
- Not checked — no full text of the sourcecites [58] Bourhill, 2017, Enzastaurin: A lesson in drug development, Crit. Rev. Oncol. Hematol. source
- Partly supportedcites [59] Wang, 2013, Marine-derived angiogenesis inhibitors for cancer therapy, Mar. Drugs sourceExperimental — accuracy not yet measured
Section 4.1 reports phase I and II bryostatin-1 trials involving all four named cancers, and the References list phase II studies for each, including colorectal cancer (ref. 132). But the paper says more than 80 phase I and II trials had been conducted since 1993; it does not support the claim that bryostatin-1 had recently entered phase II trials. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [60] Ritchie, 2015, Cancer research UK centre for drug development: Translating 21st-century science into the cancer medicines of tomorrow, Drug Discov. Today source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Based on modern research, cultured benthic cyanobacteria from temperate marine environments provide a promising, under-exploited source for novel drugs against leukemia [107].”
§ Marine Natural Products: A Source of Novel Anticancer Drugs > 5. From Marine Organisms to Anticancer Drugs > 5.1. Marine Plants
What the sources say
- Could not verifycites [107] Peng, 2010, Structure and absolute configuration of karlotoxin-2, an ichthyotoxin from the marine dinoflagellate Karlodinium veneficum, J. Am. Chem. Soc. sourceExperimental — accuracy not yet measured
The Abstract describes karlotoxin-2 from the marine dinoflagellate Karlodinium veneficum and its toxicity to fish. Searches for benthic cyanobacteria and leukemia found no passage addressing their potential as a source of leukemia drugs. (LLM, conf=0.77)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Could not verify
69 more claims · 15 with their cited sources checked
Create a free account to see all 110 claims and to verify the 12 references still open.
- It may state two separate claims as one. 23
- Probably not a substantial claim. 18
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Marine Natural Products: A Source of Novel Anticancer Drugs > 5. From Marine Organisms to Anticancer Drugs > 5.1. Marine Plants
“against KB cells and 5 µg/mL against LOVO cells (colon cancer)”
§ Marine Natural Products: A Source of Novel Anticancer Drugs > 5. From Marine Organisms to Anticancer Drugs > 5.1. Marine Plants
“against human epidermoid carcinoma (LOVO) and human colorectal adenocarcinoma (KB) cell lines”
Citations
Cites
Items 201–215 of 215
Ha, Y. N., Song, S., Orlikova-Boyer, B., Cerella, C., Christov, C., Kijjoa, A., & Diederich, M. F. (2020) · Marine Drugs · doi:10.3390/md18010057 · Cited by 16
Wang, L., Groβe, T., Stevens, H., Brinkhoff, T., Simon, M., Liang, L., Bitzer, J., Bach, G., Zeeck, A., Tokuda, H., et al. (2006) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-006-0370-1 · Cited by 15
Revision of the Structure of Acremine P from a Marine-Derived Strain of Acremonium persicinum
Garson, M., Hehre, W., Pierens, G., & Suciati (2017) · Molecules · doi:10.3390/molecules22040521 · Cited by 15 · cited 1×
“, acremines P was isolated from a marine-derived strain of Acremonium persicinum and identified using NMR techniques [52].”
Method(1992) · PubMed · Cited by 14
Langerhans cell migration is modulated by N-sulfated glucosamine moieties in heparin
O'Sullivan, G. M., Boswell, C. M., & Halliday, G. M. (2000) · Experimental Dermatology · doi:10.1034/j.1600-0625.2000.009001025.x · Cited by 13
Dziarski, R. (1992) · Cellular Immunology · doi:10.1016/0008-8749(92)90316-h · Cited by 12
Seaweed as a new source of flavone, scutellarein 4'-methyl ether
Sabina, H., & Aliya, R. (2009) · Pakistan Journal of Botany · Cited by 11
Huang, C., Leung, R. K.-K., Guo, M., Tuo, L., Guo, L., Yew, W. W., Lou, I., Lee, S. M. Y., & Sun, C. (2016) · Scientific Reports · doi:10.1038/srep20667 · Cited by 11
Phase II study of ET-743 in advanced soft-tissue sarcoma (ASTS) in adult: A STBSG-EORTC trial
Cesne, A. L., Judson, I. R., Radford, J. A., Blay, J., van Oosterom, A., Rodenhuis, S., Lorigan, P. C., Paola, E. D., Jimeno, J. M., & Verweij, J. J. (2000) · Research Explorer (The University of Manchester) · Cited by 9
Bioactive compounds from marine yeast inhibits lung cancer
Sekar, M., Poomalai, S., Gunasekaran, M., Mani, P., & Krishnamurthy, A. (2015) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2015.58.s2 · Cited by 8
Ritchie, J. W. A., & Williams, R. J. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.03.006 · Cited by 7
CYTOTOXIC EFFECTS OF THE RED SEA SOFT CORAL SARCOPHYTON TROCHELIOPHORUM.
EI‐Seedi, H. R., Gomaa, M. S., Salem, M. M., et al. (2016) · PubMed · Cited by 4
Self-citation(2006) · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS · Cited by 3
Goldin (1977) · doi:10.1002/1097-0142(197711)40:5+<2421::aid-cncr2820400905>3.0.co;2-i
Rinehart (2000) · doi:10.1002/(sici)1098-1128(200001)20:1<1::aid-med1>3.0.co;2-a
Research works printed but not linked: 7
- Whitman, 1998, The unseen majority, Proc. Natl. Acad. Sci. USA, 74, 5088
- Reyes, 2002, The marine pharmacy: New antitumoral compounds from the sea, Pharm. News, 9, 495
- Laatsch, H. (2011). AntiBase 2011: The Natural Compound Identifier, Wiley-Vch.
- Harmon, 2000, Ecteinascidin-743 (et-743) induces objective responses and disease control in patients with advanced non-osseous sarcomas: Results from phase Ii trials, Ann. Oncol., 11, 126
- Lavakumar, 2012, Anticancer and antioxidant effect of Acanthophora spicifera against EAC induced carcinoma in mice, J. Pharm. Res., 5, 1503
- Suja, 2014, Anticancer activity of compounds isolated from marine endophytic fungus Aspergillus terreus, World J. Pharm. Pharm. Sci., 3, 661
- Devi, 2015, Molecular modeling, quantitative structure activity relationship and pharmacophore studies on antiǧviral, antiǧmalarial and antiǧinflammatory bioactive compounds from marine sources, Asian J. Pharm. Clin. Res., 8, 36
Cited by
Review on natural products databases: where to find data in 2020
Sorokina, M., & Steinbeck, C. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00424-9 · Cited by 485
“The Dictionary of Natural products (DNP) [25] and it’s autonomous sub-sections, the Dictionary of Marine Natural Products (DNMP) [28] and the Dictionary of Food Compounds [29], are the considered as the most complete and best-curated resources for NP. NaprAlert [30] was created by researchers at the University of Chic…”
BackgroundInfluentialMicroalgae: therapeutic potentials and applications
Khavari, F., Saidijam, M., Taheri, M., & Nouri, F. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06422-w · Cited by 257
“Bioactive compounds of blue-green algae can induce apoptosis and activate the protein kinase-c family in cancer cells [55].”
BackgroundReher, R., Kim, H. W., Zhang, C., Mao, H. H., Wang, M., Nothias, L.-F., Caraballo-Rodriguez, A. M., Glukhov, E., Teke, B., Leao, T., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b13786 · Cited by 215
Biomaterials from the sea: Future building blocks for biomedical applications
Wan, M.-C., Qin, W., Lei, C., Li, Q.-H., Meng, M., Fang, M., Song, W., Chen, J.-H., Tay, F., & Niu, L.-N. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.04.028 · Cited by 171
Self-citationCurcumin-Based Nanoformulations: A Promising Adjuvant towards Cancer Treatment
Ghoran, S. H., Calcaterra, A., Abbasi, M., Taktaz, F., Nieselt, K., & Babaei, E. (2022) · Molecules · doi:10.3390/molecules27165236 · Cited by 160
“Due to their biochemical structures, natural compounds can affect numerous cellular targets, such as genes and proteins [4,5].”
Background
Metadata
- Authors
- Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., Chang, F.-R., Iwasaki, A., Suenaga, K., Alajlani, M., Göransson, U., & El-Seedi, H. R.
- Affiliations
- Karolinska University Hospital (SE)
- University of Kalamoon (SY)
- Cairo University (EG)
- Fujian Agriculture and Forestry University (CN)
- Quaid-i-Azam University (PK)
- Johannes Gutenberg University Mainz (DE)
- Kuwait University (KW)
- Department of Chemistry, Faculty of Science, University of Kuwait, 13060 Safat, Kuwait
- University of Karachi (PK)
- Kaohsiung Medical University (TW)
- Keio University (JP)
- Uppsala University (SE)
- Jiangsu University (CN)
- Corresponding author
- El-Seedi, Hesham R.
- ORCID
- Venue
- Marine Drugs
- Publisher
- MDPI AG
- Published
- 2019-08-23
- Volume
- 17
- Issue
- 9
- Pages
- 491
- ISSN
- 1660-3397 (ISSN-L)
- PMC
- PMC6780632
- OpenAlex
- W2969876208
- Semantic Scholar
- fc04613de468c55e3c00acaa04bbf85967f96088
- Cited by
- 555
- References
- 235
- Citations by year
- 2026: 32 · 2025: 73 · 2024: 100 · 2023: 88 · 2022: 109 · 2021: 98 · 2020: 49 · 2019: 4
- FWCI
- 6.25
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Marine Drugs (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Uppsala University (Swedish Research links grant 2016-05885 (VR for the years 2017 - 2019))
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Marine Sponges and Natural Products
- Life Sciences › Agricultural and Biological Sciences › Aquatic Science › Seaweed-derived Bioactive Compounds
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Keywords
- marine natural products, anticancer agents, marine organisms, marine algae, marine bacteria, actinomycetes, marine fungi, marine sponges, soft coral, marine plants, apoptosis, cytotoxicity, cancer prevention, molecular mechanisms, bioactive metabolites, anticancer drug discovery
- MeSH terms
- Animals, Antineoplastic Agents, Biological Products, Clinical Trials as Topic, Disease Models, Animal, Humans, Neoplasms, Treatment Outcome, Aquatic Organisms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.